Skip to main content

Research Repository

Advanced Search

PIONEER5: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment

Project Image

People Involved

Thozhukat Sathyapalan

Lisa Baldwin

Project Description

Primary objective:
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin on glycaemic control in subjects with type 2 diabetes mellitus and moderate renal impairment.
Secondary objectives:
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin on body weight in subjects with type 2 diabetes mellitus and moderate renal impairment.To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin in subjects with type 2 diabetes mellitus and moderate renal impairment

Type of Project Project
Project Acronym PIONEER5
Status Project Complete
Funder(s) Novo Nordisk
Value £27,085.00
Project Dates Nov 1, 2016 - Oct 31, 2019